Cross Country Healthcare (CCRN) Q4 2025 earnings review
Aya Merger Collapses, Core Business Seeks the Bottom
Cross Country's Q4 was defined by the termination of the Aya merger, which triggered a massive $77.9M goodwill impairment and cratered the bottom line. Beyond the deal collapse, the core staffing business continues to bleed. Revenue fell 24% YoY, and Adjusted EBITDA margins collapsed to 1.7%. Management attempts to spin a turnaround story, citing an improving market and an end-of-2026 revenue run-rate target of $1 billion. However, Q1 2026 guidance implies flat sequential revenue and continued margin pressure, suggesting the company is merely stabilizing at the trough rather than staging an immediate recovery.
🐂 Bull Case
The company emerged from the failed merger with $108.7M in cash, zero debt, and a $20M breakup fee. They are aggressively using this to buy back stock at cyclical lows (800K shares retired in Q4).
Q1 2026 revenue guidance of $235M-$240M implies the sequential bleeding is finally stopping. Management expects sequential progression throughout the year.
🐻 Bear Case
Adjusted EBITDA margin dropped from 3.0% a year ago to just 1.7%. Volumes and bill rates are falling simultaneously, completely destroying operating leverage.
The non-travel segments were supposed to be the anchor. Instead, Physician Staffing saw a sudden 20% YoY revenue collapse in Q4 as days filled plummeted.
⚖️ Verdict: 🔴
Bearish. While the pristine balance sheet limits downside risk, the sheer lack of operating profitability and the sudden collapse of previously growing segments (Physician Staffing) outweigh the cash generation narrative. Management's 2026 exit goals look overly ambitious compared to current trajectory.
Key Themes
Merger Fallout & Goodwill Impairment
The terminated Aya Merger Agreement resulted in a staggering $77.9M goodwill and trade name impairment charge, triggered by the subsequent drop in the company's equity market capitalization. The deal distraction throughout 2025 leaves the company 'unencumbered' but playing from behind in a challenging macro environment for travel staffing.
Physician Staffing: From Driver to Laggard
Reversing trend. Physician Staffing was the lone bright spot early in the year, growing 9% YoY in Q1. In Q4, the segment fell off a cliff: revenue dropped 20% YoY and total days filled plummeted 27% (from 25,427 to 18,599). This severe drop in volume suggests demand destruction has spread beyond nursing into locums.
Core Operating Cash Flow Actually Negative
Management touted 'continued positive cash flow from operations' of $18.2M for the quarter. However, this includes the $20.0M termination fee paid by Aya. Stripping out this one-time windfall reveals that underlying operations actually burned roughly $1.8M in cash during Q4—a stark contradiction to the positive cash flow narrative.
Intellify Adoption and Offshore Cost Savings
Technology and structural cost cuts are doing the heavy lifting to keep EBITDA positive. The proprietary Intellify platform is now live with 95% of MSP and vendor-neutral clients, processing 5.7 million hours in 2025. Concurrently, CCRN reduced its US headcount by 21% over the year, shifting operations to its India center of excellence to protect margins.
Pricing vs Volume Double Whammy
Decelerating. In the core Nurse and Allied Staffing segment, the company is fighting a two-front war. Average field contract personnel (FTEs) fell 17% YoY to 6,318, while the average revenue per FTE per day also dropped 8% (from $363 to $333). Without pricing power to offset volume declines, gross margins remain permanently suppressed.
Other KPIs
A massive fortress balance sheet for a company of this market cap. Cash is up from $81.6M at the end of 2024, supported by the $20M merger termination fee. Debt remains at zero. This liquidity enabled the aggressive buyback of 800,000 shares (2.5% of float) in Q4 alone.
Alongside the goodwill impairment, the company took a massive non-cash charge against its deferred tax assets. This signals that management and auditors have significantly lowered their projections for future taxable income.
Guidance
Stable sequentially. The midpoint implies a 19% YoY decline, but crucially, it represents a flat trajectory compared to Q4's $236.8M. This supports management's claim that the market could be finding a bottom.
Stable sequentially, but disastrously low historically. The midpoint implies a 1.9% margin. Despite aggressive US headcount reductions and offshore shifts, the lack of operating leverage means profitability will remain negligible until top-line growth returns.
Accelerating. Management provided a longer-term exit target for 2026. Given Q1 is starting at a ~$950M annualized run-rate with ~1.9% margins, achieving this will require a sharp acceleration in demand and pricing leverage in the back half of the year.
Key Questions
Physician Staffing Collapse
Physician Staffing volumes dropped 27% year-over-year in Q4 after growing in the first half of the year. What specific specialties or client types drove this sudden reversal, and is this a structural shift in locum tenens demand?
Bridge to 4-5% Margins
You are guiding to an exit run-rate margin of 4-5% by the end of 2026, yet Q1 guidance points to 1.9%. With US headcount already reduced by 21%, what specific pricing actions or mix shifts will drive this massive 200+ bps margin expansion?
Organic Cash Generation
Excluding the $20M Aya termination fee, operating cash flow appeared negative in Q4. Given the ongoing margin pressure, when do you expect underlying operations to consistently generate positive free cash flow again?